Ge Long Hui·2025-08-19 00:15Group 1 - The core point of the news is that Rongchang Biologics has entered into a licensing agreement with Santen Pharmaceutical (China) Co., Ltd. for the RC28-E injection, granting Santen exclusive rights for development, production, and commercialization in several regions, while retaining global rights outside these areas [1][2] - The agreement includes a non-refundable upfront payment of 250 million RMB, milestone payments that could total up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones [1] - The licensing agreement is set to take effect on August 18, 2025, and will remain valid unless terminated early according to its terms [1] Group 2 - The signing of the licensing agreement is expected to accelerate market access and patient coverage for RC28-E, significantly shortening the commercialization cycle and providing innovative solutions for the treatment of retinal diseases [2] - Santen Pharmaceutical, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd., has over 130 years of history in the ophthalmic field and is a leader in the global ophthalmic market, focusing on the development, production, and sale of ophthalmic drugs and medical devices [2]